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I n the treat of patients with advanced or recurrent breast cancer,  docetaxel is one of the drugs to use 
as standard treatment.  The recommended dose of 
docetaxel in patients with advanced or recurrent 
breast cancer is 60 to 100 mg/m2 (https://www.nccn.
org/professionals/physician_gls/f_guidelines.asp,  
http://www.cancer.gov/types/breast) [1-3].  Harvey 
showed that the tumor response rates in patients who 
received 60,  75,  and 100 mg/m2 docetaxel monother-
apy were 22.1 ,  23.3 ,  and 36.0 ,  respectively,  
and there was a signiﬁcant relationship between the 
dose and response [4].  In Europe and the Unite 
States,  docetaxel is approved for use at 100 mg/m2,  
which is also the dose recommended by Japanese 
guidelines of the therapy of breast cancer.
　 However,  the approved dose in Japan is up to 
75 mg/m2,  due to lack of evidence in Japanese 
patients.  Taguchi [5] demonstrated the pharmacoki-
netics,  tolerability,  and safety of 70-90 mg/m2 
docetaxel in Japanese patients but did not evaluate 
100 mg/m2 docetaxel.  Nakamura [6] used 100 mg/m2 
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Docetaxel is a standard treatment for patients with advanced or recurrent breast cancer.  The recom-
mended dose is 60 to 100 mg/m2.  Previous study have shown that the tumor response rates of patients 
who received docetaxel monotherapy at doses of 60,  75,  and 100 mg/m2 were 22.1 ,  23.3 ,  and 
36.0 ,  respectively,  and there was a signiﬁcant relationship between the dose and response.  In 
Europe and the United States,  docetaxel is approved at a dose of 100 mg/m2,  and Japanese guidelines 
also recommend a dose of 100 mg/m2.  However,  the approved dose in Japan is up to 75 mg/m2.  We 
have launched a phase I trial evaluating 100 mg/m2 docetaxel in patients with advanced or relapsed 
breast cancer.  The major eligibility criteria are as follows: age 20 years,  pathologically diagnosed 
breast cancer,  recurrent or advanced breast cancer,  a good performance status,  and HER2 [human 
epidermal growth factor receptor 2] negative.  The primary endpoint is demonstrated safety of 
100 mg/m2 docetaxel.  This study will clarify whether 100 mg/m2 docetaxel can be administrated safely 
in Japanese patients with advanced or recurrent breast cancer.
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docetaxel for neoadjuvant therapy of primary breast 
cancer.  Because no pharmacokinetic or safety data for 
100 mg/m2 docetaxel are available in Japanese 
patients with advanced or recurrent breast cancer,  we 
aim to evaluate the pharmacokinetics,  tolerability,  
and safety of 100 mg/m2 docetaxel in Japanese 
patients with advanced or relapsed breast cancer.  
(UMIN registration No. 000015820)
Endpoints
　 This study aims to evaluate the safety of 100 mg/m2 
docetaxel in advanced or recurrent breast cancer 
patients.  Secondary outcome measures include phar-
macokinetic/pharmacodynamic data and eﬃcacy.
　 We have launched a phase I trial.  Six patients 
from Okayama University Hospital and NHO Kure 
Medical Center will be enrolled.  All patients will 
receive 100 mg/m2 docetaxel.
Eligibility Criteria
　 The main inclusion and exclusion criteria are listed 
in Table 1.  Written informed consent must be 
obtained from patients before performing any screen-
ing or inclusion procedure.  This study is conducted in 
accordance with the Declaration of Helsinki and Good 
Clinical Practice Guidelines,  and the protocol has 
been approved by the institutional review board of 
(Okayama University Hospital,  No. 260201).
Treatment Methods
　 The treatment will be repeated every 3 weeks at 
the same dose.  The treatment will be continued until 
the patient meets the cancellation criteria.  Docetaxel 
at a dose of 100 mg/m2,  diluted in 250 ml physiologi-
cal saline or 5  glucose solution,  will be administered 
by intravenous infusion over 1 h once every 3 weeks.  
In the ﬁrst cycle,  all patients will be given 16 mg 
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Table 1　 Patient eligibility
Inclusion criteria
Aged 20 years or older
Pathologically proven breast cancer
Recurrent breast cancer that is stage IV,  unresectable,  or unsuitable for radiotherapy
Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
Adequate organ function as deﬁned below: hemoglobin level 8 g/dl,  neutrophil count 1,500/μl,  platelets 100,000/μl,  aspartate 
aminotransferase/alanine transaminase levels 2.0-fold the institutional upper limit of normal (ULN),  total bilirubin level 1.5 mg/dl,  
alkaline phosphatase level 2.5-fold the institutional ULN,  creatinine level 1.0 mg/dl
More than 2 weeks since surgery,  more than 2 weeks since chemotherapy or hormone therapy,  or more than 2 weeks since radiation 
therapy
A life expectancy of 3 months
Negative human epidermal growth factor receptor 2 (HER2) status or positive HER2 status but unsuitable for anti-HER2 therapy
Recovery of all clinically important toxicities from previous treatments to lower than grade 1 according to the Common Terminology 
Criteria for Adverse Events,  v4.0 (CTCAE v4)
Written informed consent from the patient herself
Exclusion criteria
History of intolerance or hypersensitivity to docetaxel,  alcohol,  or drugs containing polysorbate 80
History of mental disease or mental manifestations that limit compliance with the study requirements
Uncontrollable active infection such as fungal,  viral,  or bacterial infection
Unstable or untreated central nervous system metastasis
Uncontrolled heart disease including cardiomyopathy,  a New York Heart Association class III or IV heart disorder,  arrhythmia,  unstable 
angina pectoris,  or heart infarction
Prior medical record of docetaxel treatment for advanced or recurrent breast cancer
Unsuitable for dexamethasone treatment
History of another malignancy within the last 5 years
HIV antibody positive,  HBs antigen positive or HCV antibody positive
Peripheral neuropathy greater than grade 2 according to the CTCAE v4.0
Pregnant or potentially pregnant or breastfeeding 
Fertile patients who do not agree to prevent conception during the period 2 weeks prior to treatment to 120 days after treatment
Patients who cannot be hospitalized for at least 15 days from the start of the ﬁrst course of treatment
dexamethasone orally on days 3 to 5,  and in the sec-
ond and subsequent cycles,  all patients will be given 
dexamethasone starting 24 h before docetaxel infu-
sions for 3 days,  because the pharmacokinetics and 
pharmacodynamics of docetaxel will be measured only 
during the ﬁrst cycle.  The treatment will be termi-
nated if disease progression or unacceptable toxicity 
is observed or if the patient refuses further treatment.  
Initiation of the next cycle of chemotherapy will be 
delayed until the neutrophil count recovers to 
1500/μl,  platelet count to 10×104/μl,  creatinine 
level to 1.0 mg/dl,  aspartate aminotransferase/ala-
nine transaminase levels to 2-fold the institutional 
upper limit of normal,  total bilirubin level to 
1.5 mg/dl,  and non-hematological toxicities to 
grade 1.  If grade 4 febrile neutropenia or grades 3 
or 4 severe non-hematological toxicities are observed 
despite supportive therapies,  the next cycle of treat-
ment will be postponed until recovery to grade 1 or 
baseline,  and docetaxel will be reduced in the next 
cycle.  If the discontinuation period is longer than 14 
days,  the treatment will be cancelled.
Pharmacokinetic Analysis
　 Blood samples for pharmacokinetic analysis will be 
obtained days 1 to 3 of the ﬁrst cycle using an indwell-
ing venous catheter placed in the arm contralateral to 
that used for drug infusion.  Two milliliters of blood 
will be collected in heparinized tubes before drug 
administration,  at the end of docetaxel infusion,  and 
0.25,  0.5,  1,  3,  5,  9,  24,  and 48 h after dosing.  
After centrifugation,  the plasma specimens will be 
stored at －80℃ until used for the assays.
　 The pharmacokinetic/pharmacodynamic data,  max-
imum concentration (Cmax),  maximum drug concentra-
tion time,  area under the blood concentration-time 
curve (AUC),  elimination rate constant,  drug half-life,  
plasma clearance,  and apparent distribution volume 
will be calculated according to the blood drug concen-
tration of each individual.  The dose proportionality of 
the Cmax and AUC and the relationship between the 
Cmax and adverse events will be evaluated.
Statistical Consideration
　 We will assess the safety,  the primary endpoint,  
by evaluating adverse events according to the Common 
Terminology Criteria for Adverse Events criteria,  
v4.0.  The 3＋3 cohort design is the most popular 
method in phase I oncology trials.  Because the cohort 
size is up to six in this design,  we planned to enroll 6 
patients in this trial.  We will evaluate patients who 
are given 100 mg/m2 docetaxel at least once from a 
group targeted for safety analysis.  We will estimate 
the incidence of adverse events as two-sided 95  con-
ﬁdence intervals based on the binominal distribution.  
Eﬃcacy,  the secondary endpoint,  will be evaluated 
according to the response rate,  progression-free sur-
vival,  and overall survival.  Progression-free survival 
will be deﬁned as the time between period to early one 
in recurrence,  exacerbation or death days from study 
registration.  Overall survival will be deﬁned as the 
time from study registration until the date of death or 
the patientʼs last visit.  Progression-free survival and 
overall survival curves will be constructed using the 
Kaplan-Meier product-limit method.
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